Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study

[1] Bristow RE(2013)Adherence to treatment guidelines for ovarian cancer as a measure of quality care Obstet Gynecol 121 1226-1234

[2] Chang J(2014)High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease Gynecol Oncol 132 403-410

[3] Ziogas A(2011)Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial JAMA 305 2295-2303

[4] Anton-Culver H(2015)Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement Brit J Obstet Gynacol 122 434-443

[5] Bristow RE(2013)Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options Hum Reprod Update 19 151-166

[6] Chang J(1998)Comparison of seven immunoassays for the quantification of CA 125 antigen in serum Clin Chem 44 1417-1422

[7] Ziogas A(2006)Minimum training recommendations for the practice of medical ultrasound Ultraschall Med 27 79-105

[8] Randall LM(2006)Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer Int J Gynaecol Obstet 95 S161-S192

[9] Anton-Culver H(2009)Ovarian cancer Lancet 374 1371-1382

[10] Buys SS(2015)Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial Lancet 387 945-956

[1] Bristow RE(2013)Adherence to treatment guidelines for ovarian cancer as a measure of quality care Obstet Gynecol 121 1226-1234

[2] Chang J(2014)High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease Gynecol Oncol 132 403-410

[3] Ziogas A(2011)Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial JAMA 305 2295-2303

[4] Anton-Culver H(2015)Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement Brit J Obstet Gynacol 122 434-443

[5] Bristow RE(2013)Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options Hum Reprod Update 19 151-166

[6] Chang J(1998)Comparison of seven immunoassays for the quantification of CA 125 antigen in serum Clin Chem 44 1417-1422

[7] Ziogas A(2006)Minimum training recommendations for the practice of medical ultrasound Ultraschall Med 27 79-105

[8] Randall LM(2006)Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer Int J Gynaecol Obstet 95 S161-S192

[9] Anton-Culver H(2009)Ovarian cancer Lancet 374 1371-1382

[10] Buys SS(2015)Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial Lancet 387 945-956